Target intelligence / Profile preview

Gap junction protein alpha-5 (connexin-40) (Cx40)

Target
Cx40
Molecular classification
Ion channel (Connexin family, gap junction channel protein), Other: Structural membrane protein forming intercellular channels
01

Overview

Gap junction protein alpha-5 (connexin-40) is a transmembrane ion channel subunit of the connexin protein family that forms gap junctions—specialized intercellular channels allowing direct diffusion of ions, metabolites, and small signaling molecules between neighboring cells. This protein is highly expressed in cardiac atrial myocytes and vascular endothelial cells, where it is essential for electrical conduction and synchronization of tissue function. Its tightly regulated expression maintains the electrophysiologic and structural integrity of the cardiovascular system. Mutations or dysregulation of GJA5 have been identified in familial and idiopathic atrial fibrillation and in congenital heart defects involving the cardiac conduction system and great vessels.

Other names
Connexin-40Cx40GJA5ATFB11gap junction protein alpha 5 40 kDaGap junction alpha-5 proteinCX40
02

Mechanism of action

Competitive or non-competitive inhibition of gap junction channels, leading to reduced cell-cell coupling and altered cardiac electrical conduction.

03

Biological functions

Cell-to-cell electrical and metabolic couplingCoordination of electrical impulses in the heart (cardiac conduction)Regulation of vascular remodeling and artery morphogenesisMaintenance of arterial identity
04

Disease associations

Cardiovascular disease (notably atrial fibrillation, atrial standstill, and congenital heart defects)Arrhythmia predisposition (idiopathic and familial atrial fibrillation)
05

Safety considerations

Therapeutic modulation risks: targeting Cx40 may disrupt essential cardiac and vascular conduction, risking arrhythmia or conduction blockOff-target effects: gap junction blockers typically lack isoform specificity, complicating safe pharmacological intervention
06

Interacting drugs

No directly approved drugs targeting GJA5/connexin-40 available for clinical use as of early 2024.

1 more in the full profile.

07

Biomarkers

GJA5 (Cx40) expression/mutation status may serve as a biomarker for atrial fibrillation susceptibility and risk stratificationUsed for congenital heart disease diagnostic panels

Beyond the preview

Go deeper on Gap junction protein alpha-5 (connexin-40) (Cx40).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gap junction protein alpha-5 (connexin-40) (Cx40).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call